> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Goals for BsUFA 3 Released
- URL: https://www.fdaweb.com/fda-goals-for-bsufa-3-released/
- Published: 2021-09-22T12:00:00.000Z
- Updated: 2026-09-14T17:15:39.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150198

In its Biosimilar User Fee Act (BsUFA) 3 goal letter for FY 2023-2027, FDA commits to responding to 90% of original biosimilar product application submissions within 10 months of the 60-day filing date and 90% of resubmitted original biosimilar product applications within six months of the receipt date. The [goal letter](https://www.fda.gov/media/152279/download?ref=fdaweb.com) has goals for: 

- ensuring the effectiveness of the biosimilar biological product review program;
- enhancing biosimilar and interchangeable biological product development and regulatory science;
- continued enhancement of user fee resource management;
- improving FDA hiring and retention of review staff; and
- information technology goals.

The agency has [scheduled](https://www.fdaweb.com/public-meeting-on-biosimilar-user-fee-reauthorization/) an 11/2 public meeting on the BsUFA reauthorization.